Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam by Kachur, S Patrick et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Malaria Journal
Open Access Research
Putting the genie back in the bottle? Availability and presentation of 
oral artemisinin compounds at retail pharmacies in urban 
Dar-es-Salaam
S Patrick Kachur*1,2, Carolyn Black1,3, Salim Abdulla1 and 
Catherine Goodman4
Address: 1Ifakara Health Research and Development Centre, Ifakara, P.O. Box 78373, Dar-es-Salaam, Tanzania, 2United States Public Health 
Service Commissioned Corps and Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease 
Control and Prevention, Atlanta, Georgia, USA, 3University of Maryland Baltimore County, Baltimore, Maryland, USA and 4Health Economics and 
Financing Programme, Health Policy Unit, London School of Hygiene and Tropical Medicine, London, UK
Email: S Patrick Kachur* - skachur@cdc.gov; Carolyn Black - black1@umbc.edu; Salim Abdulla - salim.abdulla@gmail.com; 
Catherine Goodman - catherine.goodman@lshtm.ac.uk
* Corresponding author    
Abstract
Background: Recently global health advocates have called for the introduction of artemisinin-
containing antimalarial combination therapies to help curb the impact of drug-resistant malaria in
Africa. Retail trade in artemisinin monotherapies could undermine efforts to restrict this class of
medicines to more theoretically sound combination treatments.
Methods:  This paper describes a systematic search for artemisinin-containing products at a
random sample of licensed pharmacies in Dar-es-Salaam, Tanzania in July 2005.
Results: Nineteen different artemisinin-containing oral pharmaceutical products, including one co-
formulated product, one co-packaged product, and 17 monotherapies were identified. All but one
of the products were legally registered and samples of each product were obtained without a
prescription. Packaging and labeling of the products seldom included local language or illustrated
instructions for low-literate clients. Packaging and inserts compared reasonably well with standards
recommended by the national regulatory authority with some important exceptions. Dosing
instructions were inconsistent, and most recommended inadequate doses based on international
standards. None of the monotherapy products mentioned potential benefits of combining the
treatment with another antimalarial drug.
Conclusion: The findings confirm the widespread availability of artemisinin monotherapies that
led the World Health Organization to call for the voluntary withdrawal of these drugs in malaria-
endemic countries. As the global public health community gathers resources to deploy artemisinin-
containing combination therapies in Africa, planners should be mindful that these drugs will coexist
with artemisinin monotherapies in an already well-established market place. In particular,
regulatory authorities should be incorporated urgently into the process of planning for rational
deployment of artemisinin-containing antimalarial combination therapies.
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Background
Artemisinin-containing combination treatments (ACTs)
are recommended to stem the rising tide of drug-resistant
malaria in Africa[1]. So far, widespread public-sector
deployment of artemisinin-containing drugs has been
constrained by their relatively high cost and limited glo-
bal supply, as well as some lingering concerns about
safety[2,3]. International attention has focused on identi-
fying sustainable resources for purchasing the needed
drugs for widescale deployment through public sector
health systems[4,5]. However, artemisinin-containing
compounds have been available in retail pharmacies in
many African countries for some time. In Tanzania, no
fewer than 31 artemisinin-containing compounds have
been registered with the Food and Drugs Authority[6].
These include a range of oral and parenteral products sold
from pharmacies as prescription only medicines.
Parenteral preparations are specifically intended to be
administered only by a trained health worker; however,
oral products–even those registered as prescription only
medicines–are frequently obtained without a prescription
and require that the patient or a caretaker make a choice
between several products and interpret the dosing instruc-
tions provided with the packaging[7]. Therefore, this
study was undertaken to identify and describe the range of
oral artemisinin products currently available in one urban
setting.
No previously published studies report on the quality of
packaging and labeling materials for artemisinin-contain-
ing medicines. Recent reports from Asia have raised ques-
tions about the quality of commercially available
artemisinin products, but have been largely limited to
details on chemical content and bioavailability[8]. The
presentation of a pharmaceutical product can encourage
or dissuade clients from selecting it. The quality of dosing
instructions, including their appropriateness for low-liter-
ate clients can have an important impact on complete
adherence. Therefore, the study aimed at describing qual-
itative aspects of presentation for these artemisinin-con-
taining products as well as their availability. These
findings were compared to national standards for the
presentation of pharmaceutical products which have been
established by the Tanzania Food and Drugs Authority
(TFDA), alongside requirements for chemical content and
bioavailability[9].
Finally, according to Tanzania's national malaria treat-
ment guidelines artemisinin monotherapies are recom-
mended only as alternative regimens for patients who
cannot tolerate the first-, second- or third-line drugs[10].
The World Health Organization (WHO) recommends
that this class of drugs be deployed only in combination
with other antimalarial drugs as a safeguard against the
development of unchecked resistance[11] and has called
for a voluntary halt to marketing the monotherapies in
malaria-endemic countries[12]. A number of national
and global recommendations pertaining to the use of
artemisinin-containing medicines have been elaborated
since the first products in this class were registered[13].
This analysis also compared the manufacturers' recom-
mended doses for these products with published interna-
tional standards.
Methods
Dar-es-Salaam is the commercial capital and largest major
urban center in Tanzania. Home to more than three mil-
lion people, it hosts a major Indian Ocean port and com-
prises three independently governed municipalities.
Malaria transmission can occur throughout the year in
Dar-es-Salaam, although the intensity of transmission in
this urban setting is far lower than elsewhere in the coun-
try. None-the-less, malaria is perceived as a very common
illness. It remains the single most common clinical diag-
nosis at health facilities in the municipalities [14]. In
addition, people commonly perceive malaria to be the
cause of nearly every uncomplicated febrile illness and
routinely seek treatment without consulting health work-
ers at registered facilities or obtaining a diagnosis[15].
Artemisinin-containing drugs are recognized as prescrip-
tion only medications in Tanzania and can be stocked
only at registered health facilities (health centres and hos-
pitals with a licensed physician or clinical officer) and
fully-licensed pharmacies (designated as Part I pharma-
cies). Thirty registered Part I pharmacies in the three
municipalities were randomly selected from a line-list of
331 such shops provided by TFDA. Based on previous
experience with similar activities in 2003 and 2004, the
study team developed a questionnaire to assess the avail-
ability of artemisinin-containing antimalarial drugs at
these shops during the first two weeks of July 2005. The
survey instrument included scanned images of 18 prod-
ucts identified in previous years and asked pharmacists to
identify any additional products in this class which were
in stock at the time of visit or within the previous three
months. The pharmacists provided the current retail price
of each product they had recently stocked. They were also
asked their opinions on which three drugs in this class
they sold most frequently. A sample of each commercial
product was purchased so that researchers could compare
the packaging and labeling information. Samples were
obtained without a prescription, but after explaining the
purpose of the study to the pharmacist in charge.
Data from the survey were entered into EpiInfo Version
6.0 (Centers for Disease Control and Prevention, Atlanta,
Georgia USA). All packaging and package inserts were
scanned into a digital format and were coded and ana-
lyzed using AtlasTi version 4.2 (Scientific Software, Berlin,Malaria Journal 2006, 5:25 http://www.malariajournal.com/content/5/1/25
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GERMANY). Elements of drug presentation were com-
pared to nationally recognized standards for labeling and
package inserts as elaborated by TFDA[9] and dosing rec-
ommendations were compared to standards established
by WHO[11].
Results
Availability, origin, price and estimated sales
Data were successfully collected in 29 pharmacies. Six of
the pharmacies selected from the line list could not be
located so other Part 1 drug stores in the same neighbor-
hoods were substituted. One additional pharmacy could
not be located and no appropriate substitute was found.
All shops had at least two artemisinin-containing prod-
ucts available on the day of the visit, and one shop had 16
different products on offer and had stocked two addi-
tional items in the previous three months. The median
number of artemisinin-containing oral pharmaceutical
products available at selected pharmacies was 13 (mean =
10.8). In all 19 different products were identified, not
including parenteral or rectal preparations. All but two
products were artemisinin monotherapies. The exceptions
were product #1 a co-formulated tablet containing arte-
mether/lumefantrine and product #2, co-packaged tablets
of artesunate and mefloquine. Nine (31%) pharmacists
indicated that they were out of stock on the day of inter-
view for one or more artemisinin-containing products
that they regularly carried within the past three months.
There was no observable trend for individual brands or
products and no product had been stocked out at more
than two outlets. The 19 products available are listed in
Table 1 below, which also compares the relative preva-
lence of each product and its mean purchase price as well
as pharmacists' perceptions of the best selling brands
Eleven of the products contained artesunate, but products
containing artemether and dihydroartemisinin were also
commonly encountered. At least one product containing
each of these compounds was identified at more than
80% of outlets. All products but one (product #11) were
registered with TFDA and sold under the labels of phar-
maceutical producers in Europe (n = 9), Asia (n = 7) and
Africa (n = 3 including the one unregistered product). One
European company was the source of four different prod-
ucts, two artesunate tablets and two artemether suspen-
sions. Another European company supplied three
products, two artesunate tablets and one product contain-
ing co-packaged artesunate and mefloquine. One Asian
company was the source of two products, both tablets and
suspension containing dihydroartemisinin. All other
Table 1: Artemisin-containing oral pharmaceutical products obtained from registered pharmacies in Dar-es-Salaam, Tanzania, 2005
Product/active 
ingredient(s)
Formulation Country of 
origin*
2005 availability
 (n = 29)
Named in the 
top 3 sellers
 in 2005 (n = 28)
Mean selling 
price 2005†
1. artemether/
lumefantrine
20/120 mg tablets, co-formulated Switzerland 21 (72.4%) 5 (17.9%) $ 7.59
2. artesunate and 
mefloquine
200 mg and 250 mg tablets, co-packaged Switzerland 17 (58.6%) 0 $ 7.05
3. artesunate 50 mg tablets China 6 (20.7%) 0 $ 4.62
4. artesunate 50 mg tablets France 24 (82.8%) 7 (25.0%) $ 5.48
5. artesunate 50 mg tablets Switzerland 8 (27.6%) 0 $ 5.26
6. artesunate 50 mg tablets Belgium 28 (96.6%) 3 (10.7%) $ 3.53
7. artesunate 50 mg tablets India 17 (58.6%) 0 $ 2.51
8. artesunate 100 mg tablets Belgium 28 (96.6%) 28 (100%) $ 4.99
9. artesunate 100 mg tablets Tanzania 7 (24.1%) 1 (3.6%) $ 2.19
10. artesunate 100 mg tablets Tanzania 20 (69.0%) 6 (21.4%) $ 1.92
11. artesunate 100 mg tablets Kenya 2 (6.9%) 0 $ 2.31
12. artesunate 200 mg tablets Switzerland 19 (65.5%) 1 (3.6%) $ 6.72
13. artemether 40 mg tablets India 8 (27.6% 0 0 $ 2.24
14. artemether 50 mg tablets China 24 (82.8%) 15 (53.6%) $ 4.74
15. artemether 180 mg/60 ml suspension Belgium 18 (62.1%) 0 $ 4.65
16. artemether 300 mg/100 ml suspension Belgium 3 (10.3%) 0 $ 5.75
17. dihydroartemisinin 60 mg tablets Korea 18 (62.1%) 0 $ 4.36
18. dihydroartemisinin 60 mg tablets China 25 (86.2%) 9 (35.7%) $ 4.55
19. dihydroartemisinin 160 mg/80 ml suspension China 20 (69.0%) 0 $ 4.18
*Country of origin refers to the address of the company holding registration for this product in Tanzania (with the exception of product 11 which 
was not registered in the country). In some cases drugs that are produced in Asia are packaged and distributed by pharmaceutical partners in Africa 
and Europe. This information was not consistently provided.
†On 15 July 2005 = US $1.00 = 1188 Tanzania shillingsMalaria Journal 2006, 5:25 http://www.malariajournal.com/content/5/1/25
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products represented the registering company's sole prod-
uct in the class. In all the 19 products identified were reg-
istered to or produced by 13 different manufacturers.
Prices ranged from 12,800 Tanzanian shillings (TSh) (US
$10.77) for an adult dose of product #1 to 1,300 TSh
($1.09) for an adult dose of product #10. The co-formu-
lated and co-packaged ACT products (products #1 and #2,
respectively) fetched the highest prices. However, at least
one artesunate monotherapy (product #12) was priced
similarly. Most of the European and Chinese mono-
therapy products sold for 5000–6000 TSh (roughly $4.00
to $5.00) for one adult dose, while those from Indian or
African manufacturers were considerably less expensive.
Prices for individual products varied among the shops,
but relative differences between specific products within a
given shop were remarkably similar across all outlets.
When asked to comment on the three best selling brands
of artemisinin-containing drugs, all 28 pharmacists who
responded named the same European brand of artesunate
monotherapy (one pharmacist declined to estimate rela-
tive sales of individual products but stocked only products
from this manufacturer). The distant second and third
Table 2: Features of packaging and labeling for oral artemisinin-containing pharmaceutical products at pharmacies in Dar-es-Salaam, 
Tanzania
Feature Frequency
General features
Packaged and sold as a unit dose 19 (100%)
Package insert included 19 (100%)
Image of mosquito appears on package 7 (37%)
TFDA Package and labeling requirements
International non-proprietary name included 19 (100%)
Non-proprietary name is printed larger or bolder* 0
Strength of active ingredient identified 19 (100%)
Name and address of registrant identified 17 (89%)
Name and address of manufacturer other than registrant identified 7 (37%)
Labeled "Keep out of reach of children" 10 (53%)
Lot or batch number 19 (100%)
Expiry date 19 (100%)
Date of manufacture 18 (95%)
TFDA Registration number 6 (32%)
TFDA Package insert requirements
Indication (uncomplicated malaria) 19 (100%)
Dosage regimen 19 (100%)
Contraindications 12 (63%)
Side effects 19 (100%)
Drug interactions 11 (58%)
Precautions and warnings 18 (95%)
Symptoms and treatment of overdose 11 (58%)
Presentation (e.g. "12 tablets of 100 mg each") 19 (100%)
Storage instructions 13 (68%)
Shelf life 14 (74%)
Name and address of manufacturer other than registrant identified 6 (32%)
Date of publication of package insert 9 (47%)
Appropriateness of recommended dose
Recommended total adult dose consistent with international standards** 4 (21%)
Recommended duration consistent with international standards*** 5 (26%)
Mentions that non-immune patients may require additional doses 2 (13%)
Gives dosages for children 17 (89%)
Specifically formulated for children 4 (21%)
*Excludes one generic product.
**At least 16 mg/kg for artesunate, artemether or dihydroartemisinin monotherapies; 9 mg/kg artemether combined with 72 mg/kg lumefantrine; or 
12 mg/kg artesunate combined with 32 mg/kg mefloquine.
***At least 7 days for artemisinin monotherapies, 6 doses of artemether/lumefantrine over 3 days, or 3 daily doses for artesunate + mefloquine.Malaria Journal 2006, 5:25 http://www.malariajournal.com/content/5/1/25
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most commonly named products were Asian brands of
artemether and dihydroartemisinin tablets, respectively.
Features of drug presentation
All of the products were sold as prepackaged unit doses,
usually sufficient for an average adult taking the manufac-
turer's recommended course of treatment. All were
obtained in the manufacturers' original packaging. Tablets
were sealed in blisters or foil sachets and powder for sus-
pension was provided in tamper-proof bottles. Each prod-
uct included the manufacturer's package insert and was
contained in a professionally manufactured box with high
quality printing using no fewer than two colors. None of
the medicines in this class were sold as loose tablets dis-
pensed from bulk containers. All but three products were
identified as antimalarial drugs on the overpackaging,
most typically in English. Only three products included
this information in Swahili. Other languages including
French, Italian, Spanish, Chinese, and Portuguese were
more commonly represented. Seven products included an
image of a mosquito on the box, which might have helped
low-literate and non-European consumers identify them
as malaria treatments. However, in at least two cases the
image was so stylized as to be of limited use for this pur-
pose.
Table 2 includes information about how well the products
matched legally recognized standards for packaging and
labeling of pharmaceutical products in Tanzania[9] Most
of the products conformed reasonably well with many of
the standards, but there were some notable exceptions.
The nonproprietary name always appeared in much
smaller type font than the commercial name, except in the
case of the single generic product. Only six products had
their Tanzanian registration number printed on the pack-
aging, suggesting many were packed for sale in multiple
countries. Two additional products were labeled with reg-
istration numbers from other countries, one each for
Nigeria and Ecuador. Seven products identified a manu-
facturer other than the registrant with statements such as
"Manufactured by Company X in Asia for Company Y in
Europe." In particular, many of the European and African
products did not mention any other partners that might
have been responsible for some stages of the production
including extraction and tablet formulation, although this
is likely to have been the case for many. Information on
contraindications, drug interactions and how to recognize
and manage overdose was inconsistently provided. Fewer
than half included a date of publication for the package
insert. Five products were packaged with inserts prepared
for two or more preparations of the same drug.
Appropriateness of recommended doses
The recommended doses for the co-formulated (product
#1) and co-packaged (product #2) ACTs were consistent
with international recommendations. The World Health
Organization recommends that artemisinin monotherapy
be used only when combination treatments are unavaila-
ble or a patient cannot tolerate another antimalarial
drug[11] and has recently called on manufacturers to
withdraw these products from markets in malaria-
endemic countries[12]. In the past, WHO recommended
that at least seven days of monotherapy and a total dose
of 16 mg/kg (1120 mg for an adult) was warranted, even
in partially immune adults[16]. One recent report among
non-immune patients suggests that even this prolonged
monotherapy may be suboptimal[17]. Investigators com-
pared the total dose of artemisinin recommended for an
adult and calculated the recommended pediatric dose for
an 18 month old child weighing 15 kg based on informa-
tion in the package inserts. Three products recommended
no adult dose. The total adult artemisinin dose recom-
mended among the other products ranged from 360 mg
(product #17) to 1200 mg (products #5 and 12). Ten
products recommended a total adult dose of 600 mg of
artemisinin. The recommended dose for an 18 month old
15 kg child was similarly variable, ranging from 105 mg
(product #11) to 450 mg (products #5 and 12) total
artemisinin dose (At lease 240 mg would be required to
comply with WHO recommendations for such a child).
Four products recommended a total aretmisinin dose of
144 mg and five recommended 180 mg for a child in this
age or weight group. Two products recommended no
pediatric doses and included the comments: "Not recom-
mended for children < 30 kg." (product #2, the co-pack-
aged product) and "Below 35 kg.: As directed by
physician" (product #10).
Aside from the total dose, the recommended duration of
therapy was inadequate for most of the products identi-
fied, particularly the artemisinin monotherapies. Of the
17 monotherapies identified, only the three dihydroar-
temisinin products recommended a seven day course of
treatment. At least two other products included a state-
ment about non-immune patients requiring additional
doses and an extended duration of therapy. None of the
monotherapy products included any information about
the advantages or disadvantages of combining treatment
with other antimalarial drugs. Thirteen products recom-
mended regimens based on single daily doses, often with
a loading dose double what was recommended on subse-
quent days. Three products recommended two doses on
the first day of treatment followed by daily doses thereaf-
ter (products #1, 12 and 13). Three artesunate mono-
therapy products recommended twice daily doses
(products #3, 4 and 7).
All of the products were packaged in unit doses. But in
most cases these were sufficient only for the substandard
doses recommended by the manufacturers. To obtain aMalaria Journal 2006, 5:25 http://www.malariajournal.com/content/5/1/25
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complete seven day treatment adult patients would have
had to purchase at least two "unit doses" of all of the arte-
mether and artesunate monotherapy products. Four prod-
ucts were specifically identified as pediatric preparations
(a 50 mg. artesunate tablet, a suspension of dihydroar-
temisinin and two preparations of artemether suspen-
sion). According to WHO recommendations, the number
of tablets or volume of suspension available for each of
these four pediatric products would have been sufficient
for children ranging from up to 9.6 kg for one product all
the way to 21.4 kg for another. Additional packages would
have to be purchased to treat larger children completely.
Discussion
A recent report from the United States (US) Institute of
Medicine (IOM) describes a twofold challenge: "to facili-
tate widespread use of artemisinins while, at the same
time, to preserve their effectiveness for as long as possi-
ble[18]." In its report, the group advances its case for a
global level subsidy combined with a coordinated world-
wide effort to procure and deploy artemisinin compounds
exclusively in combination therapies co-formulated with
other antimalarial drugs. Among other proposed advan-
tages, the IOM authors anticipate that this approach
would empower the global community to dissuade partic-
ipating manufacturers from producing and promoting
artemisinin monotherapies. Assuming the resource and
production constraints are overcome and the global pro-
curement mechanism established within the next 5 years
it is important to recognize that unsubsidized, dynamic
retail markets for artemisinin monotherapies are already
established–and thriving–particularly in urban centers. A
recent plea from the World Health Organization to per-
suade manufacturers to withdraw monotherapies from
markets in endemic countries is welcome, but cannot be
effectively enforced without the cooperation of industry
and regulatory officials[12].
The findings suggest that this challenge be addressed as
urgently as possible. They confirm that artemisinin-con-
taining oral pharmaceutical products are already widely
available at pharmacies in urban Dar-es-Salaam and
underscore the urgency with which WHO called for an
immediate halt to their proliferation. The number and
range of products described in this study were nearly iden-
tical in a similar activity completed a year prior (the 2004
survey identified 17 products). While the implementation
of an ACT for first-line malaria treatment in the public sec-
tor has been delayed in Tanzania by the need for donor
support and a global shortage of raw material for artemisi-
nin production[19], relatively few of the pharmacies vis-
ited had stocked out of these drugs at any time in recent
memory. In addition to their broad availability, the prod-
ucts ranged widely in price. Although some were priced
well beyond the reach of most Tanzanian consumers, the
most affordable items in this class were priced only 50%
higher than European products containing sulfadoxine/
pyrimethamine, the currently recommended first-line
treatment for malaria.
While many of the national standards for packaging and
labeling were met, most products were packaged for mon-
otherapy and dosing instructions varied as much as four
fold across the range of products. In addition, most prod-
ucts recommended doses that were insufficient based on
international recommendations. An additional issue of
concern with the presentation of these products is that the
regulatory requirements assume that the drugs will be
available by prescription only. For that reason they
include a level of detail that is appropriate for a physician
or pharmacist, but would be very difficult for even an Eng-
lish-literate lay person to interpret. Recognizing that for
the most part antimalarial drugs are dispensed and pur-
chased not by trained health professionals, but by ordi-
nary consumers, WHO has recently produced
specifications for prepacking antimalarial medica-
tions[20]. Their report also recommends that careful
packaging should be coupled with information, educa-
tion and communication efforts to optimize consumers'
ability to adhere to recommended therapies and dosing
regimens. Malaria control officials and regulatory author-
ities may wish to reconsider their current requirements in
light of these new specifications, particularly in countries
like Tanzania, where a new national treatment policy rec-
ommending ACT is about to be launched.
These observations are discouraging. However, it is
important to note that in Tanzania this complex market
for artemisinin-based drugs is still relatively contained
within major urban centres. The availability of pharma-
cies and expensive medical products in rural areas, where
most malaria transmission occurs, is far more limited. In
rural Tanzania, for example, drug shops seldom promote
antimalarials other than the recommended first- and sec-
ond-line drugs [21]; artemisinin-containing treatments
are found only occasionally[22]. Nevertheless, the find-
ings point to the urgent need for malaria control officials
and drugs regulatory authorities in malaria-endemic
countries to plan for a coordinated and rational deploy-
ment of artemisinin-containing antimalarial drugs. In
Tanzania, and a number of other countries, the Ministry
of Health anticipates introducing ACTs for first-line treat-
ment of uncomplicated malaria as early as 2006[23]. It is
unlikely that the global subsidy as recommended by IOM
will have materialized by that time and it is unrealistic to
expect that established products will be retrenched with-
out substantial intervention. But funds are available to
make a highly subsidized ACT available at public sector
health facilities which could discourage many clients from
resorting to relatively expensive treatments at pharmacies.Malaria Journal 2006, 5:25 http://www.malariajournal.com/content/5/1/25
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However, people will continue to rely on retail sector
sources for their flexibility and convenience[21] and some
of the products identified are approaching affordability
and can be expected to become ever more widely availa-
ble. Interventions to expand the availability of ACT for
home and community management of malaria might
offer one way to work actively with pharmaceutical retail-
ers to achieve high coverage and minimize misuse of
monotherapies[24], but such an approach is unlikely to
be appropriate everywhere ACTs are used[25]. Improved
packaging and presentation might also be employed to
enhance the likelihood that those who obtain artemisi-
nin-containing drugs complete the recommended
dose[26].
No single solution will likely reverse the current trend as
countries move quickly to roll out ACTs. Rather, malaria
control officials and drugs regulatory authorities will have
to negotiate solutions and develop adaptive practices if
the twin goals of achieving broad access and safeguarding
against resistance are to be feasible. Monitoring the avail-
ability and presentation of already registered products, as
well as carefully considering applications for registering
new products should be undertaken as soon as possible.
Reconsidering packaging and labeling requirements so
that they result in more useful information and are con-
sistent with national and international guidelines would
go a long way to improving the situation as well. It may be
a long while before a global subsidy on ACTs achieves the
goal of crowding out artemisinin monotherapy products–
if such a development ever occurs. Engaging pharmaceuti-
cal producers and regulators in the process of rationally
rolling out ACT to meet the needs of malaria-endemic
countries where traditional antimalarial drugs have
become ineffective may be a more constructive way for-
ward in the short- to medium-term.
Conclusion
Artemisinin-containing monotherapies are already widely
available in retail pharmacies in Tanzania and elsewhere,
even while public health officials struggle to introduce
more rational ACTs and global authorities have called for
the recall of single drug treatments in this class. Packaging
and labeling of these commercially available products is
highly variable and manufacturers generally recommend
insufficient doses and duration of therapy based on inter-
national recommendations. National and international
plans to deploy ACTs should urgently engage pharmaceu-
tical manufacturers and drugs regulatory authorities or
risk undermining the long term utility of this entire class
of drugs.
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